Literature DB >> 20923711

Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.

Bruce Y Lee1, Angela R Wateska, Rachel R Bailey, Julie H Y Tai, Kristina M Bacon, Kenneth J Smith.   

Abstract

Enterovirus 71 (EV71) is a growing public health concern, especially in Asia. A surge of EV71 cases in 2008 prompted authorities in China to go on national alert. While there is currently no treatment for EV71 infections, vaccines are under development. We developed a computer simulation model to determine the potential economic value of an EV71 vaccine for children (<5 years old) in China. Our results suggest that routine vaccination in China (EV71 infection incidence ≈0.04%) may be cost-effective when vaccine cost is $25 and efficacy ≥70% or cost is $10 and efficacy ≥50%. For populations with higher infection risk (≥0.4%), a $50 or $75 vaccine would be highly cost-effective even when vaccine efficacy is as low as 50%.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923711      PMCID: PMC2989421          DOI: 10.1016/j.vaccine.2010.09.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  Pricing of new vaccines.

Authors:  Bruce Y Lee; Sarah M McGlone
Journal:  Hum Vaccin       Date:  2010-08

2.  Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia.

Authors:  Denise DeRoeck; John D Clemens; Andrew Nyamete; Richard T Mahoney
Journal:  Vaccine       Date:  2005-04-15       Impact factor: 3.641

Review 3.  Enteroviruses as agents of emerging infectious diseases.

Authors:  G Palacios; M S Oberste
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

4.  Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement.

Authors:  G L Gilbert; K E Dickson; M J Waters; M L Kennett; S A Land; M Sneddon
Journal:  Pediatr Infect Dis J       Date:  1988-07       Impact factor: 2.129

5.  Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan.

Authors:  Luan-Yin Chang; Chwan-Chuen King; Kuang-Hung Hsu; Hsiao-Chen Ning; Kuo-Chien Tsao; Chung-Chen Li; Yhu-Chering Huang; Shin-Ru Shih; Shu-Ti Chiou; Po-Yen Chen; Hong-Jen Chang; Tzou-Yien Lin
Journal:  Pediatrics       Date:  2002-06       Impact factor: 7.124

6.  Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection.

Authors:  Hsiao-Ling Chen; Jiun-Yan Huang; Te-Wei Chu; Tung-Chou Tsai; Che-Ming Hung; Chih-Cheng Lin; Fang-Chueh Liu; Li-Chung Wang; Yi-Ju Chen; Ming-Fong Lin; Chuan-Mu Chen
Journal:  Vaccine       Date:  2008-04-10       Impact factor: 3.641

Review 7.  Human enterovirus 71 and hand, foot and mouth disease.

Authors:  S S Y Wong; C C Y Yip; S K P Lau; K Y Yuen
Journal:  Epidemiol Infect       Date:  2010-01-08       Impact factor: 2.451

8.  Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis.

Authors:  Marc Jeuland; Joseph Cook; Christine Poulos; John Clemens; Dale Whittington
Journal:  Value Health       Date:  2009-09       Impact factor: 5.725

9.  Cost-effectiveness of HPV 16, 18 vaccination in Brazil.

Authors:  Sue J Goldie; Jane J Kim; Katie Kobus; Jeremy D Goldhaber-Fiebert; Joshua Salomon; Meredith K H O'shea; F Xavier Bosch; Silvia de Sanjosé; Eduardo L Franco
Journal:  Vaccine       Date:  2007-06-15       Impact factor: 3.641

10.  The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico.

Authors:  Delphine Hu; Stefano M Bertozzi; Emmanuela Gakidou; Steve Sweet; Sue J Goldie
Journal:  PLoS One       Date:  2007-08-15       Impact factor: 3.240

View more
  25 in total

1.  A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions.

Authors:  Yueyuan Zhao; Xuefeng Zhang; Fengcai Zhu; Hui Jin; Bei Wang
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 2.  Is a multivalent hand, foot, and mouth disease vaccine feasible?

Authors:  Michel Klein; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015-05-26       Impact factor: 3.452

3.  A systems approach to vaccine decision making.

Authors:  Bruce Y Lee; Leslie E Mueller; Carla G Tilchin
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

4.  Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Authors:  Xiaoqing Cheng; Yueyuan Zhao; Xuefeng Zhang; Hui Jin; Jie Min
Journal:  Hum Vaccin Immunother       Date:  2017-04-27       Impact factor: 3.452

Review 5.  Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.

Authors:  S Aswathyraj; G Arunkumar; E K Alidjinou; D Hober
Journal:  Med Microbiol Immunol       Date:  2016-07-12       Impact factor: 3.402

6.  A case-control study of risk factors for severe hand-foot-mouth disease in Yuxi, China, 2010-2012.

Authors:  Ze Liu; Shukun Wang; Rusong Yang; Xia Ou
Journal:  Virol Sin       Date:  2014-04       Impact factor: 4.327

Review 7.  Host factors in enterovirus 71 replication.

Authors:  Shin-Ru Shih; Victor Stollar; Mei-Ling Li
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

8.  The Pathogenesis and Prevention of Encephalitis due to Human Enterovirus 71.

Authors:  Emily Jane Bek; Peter Charles McMinn
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

9.  Disease burden of enterovirus 71 in rural central China: A community-based survey.

Authors:  Zheng-kai Gan; Hui Jin; Jing-xin Li; Xue-jun Yao; Yang Zhou; Xue-feng Zhang; Feng-cai Zhu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Cost effectiveness of medical devices to diagnose pre-eclampsia in low-resource settings.

Authors:  Zoë M McLaren; Alana Sharp; John P Hessburg; Amir Sabet Sarvestani; Ethan Parker; James Akazili; Timothy R B Johnson; Kathleen H Sienko
Journal:  Dev Eng       Date:  2017-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.